The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients

Immunological Investigations

Volumn 39, Issue 8, 2010, Pages 820-832

  Salah, Hosam ^a   Atfy, Maha ^a   Fathy, Ayman ^a   Atfy, Mervat ^a   Mansor, Hosam ^a   Saeed, Jehan ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

OPG RANKL ratio; Osteopenia; Osteoporosis; Thalassemia

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CHILD; CONTROL GROUP; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EGYPT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; YOUNG ADULT;

EID: 77958196430     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2010.498492     Document Type: Article

References (31)

1. Al-Mahroos, F. T., Ebrahim, A. (1995). Prevalence of hepatitis B, Hepatitis C and human immune deficiency virus markers among patients with hereditary haemolytic anemias. Ann. Trop. Paediat. 15:121-128.
2. Angelopoulos, N. G., Goula, A., Katounda, E., Rombopoulos, G., Kaltzidou, V. (2007). Markers of bone metabolism in eugonadal female patients with thalassemia major. Pediat. Hematol. Oncol. 24:481-491.
3. Angelopoulos, N. G., Katounda, E., Kaltzidou, V. (2007). Circulating osteoprotegerin and receptor activator of NF-κB ligand system in patients with 13-thalassemia major. J. Bone Miner. Metabol. 25:60-67.
4. Baudhuin, M., Lamoureux, F., Duplomb, L., Redini, F., Heymann, D. (2007). RANKL, RANK, Osteoprotegerin: Key partners of Osteoimmunology and vascular diseases. J. Cell. Mol. Life Sci. 64:2334-2350.
5. Boroujerdnia, M., Zadegan, M., Zandian, K., Rodan, M. (2009). Prevalence of hepatitis-C virus (HCV) among thalassemia patients in Khuzestan Province, Southwest Iran. Pakis. J. Med. Sci. 25 (1):113-117.
6. Deeks, E. D., Perry, C. M. (2008). Zoledronic acid: A review of its use in the treatment of osteoporosis. Drugs Aging 25 (11):963-986.
7. El-Beshlawy, A., Kaddah, N., Rageb, L., Hussein, I., Mouktar, G., Moustafa, A., Elraouf, E., Hassaballa, N., Gaafar, T., El-Sendiony, H. (1999). Thalassemia prevalence and status in Egypt. Pediat. Res. 45 (5):760-766.
8. El-Gohary, A., Hassan, A., Nooman, Z., et al. (1995). High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop. 59:155-161.
9. Forget, B. G., Cohen, A. R. (2005). Thalassemia Syndromes, in Hoffman: Hematology: Basic Principles and Practice, Hoffman, R., Benz, E. J., Shattil, S. J., Furie, B., Cohen, H. J., Silberstein, L. E., McGlave, P. (eds.), 4th ed., Chapter 35, Philadelphia: Churchill Livingstone, pp. 1456-1478.
10. Fox, S. W., Haque, S. J., Lovibond, A. C., Chambers, T. J. (2003). The possible role of TGF-B-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J. Immunol. 170:3679-3687.
11. Gao, Y. H., Shinki, T., Yuase, T., et al. (1998). Potential role of osteoblastic transcription factor-l, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor. Biochem. Biophys. Res. Commun. 252:697-702.
12. Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., Riggs, B. L. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15:212-219.
13. Hussein, G., Fawzy, M., EI Serafi, T., Ismail, E. F., El Metwally, D., Saber, M. A., Giansily, M., Schved, J., Pissard, S., Martinez, P. A. (2007). Rapid detection of beta-Thalassemia alleles in Egypt using naturally or amplified created restriction sites and direct sequencing: A step in disease control. Hemoglobin 31:49-62.
14. Isomura, H., Fujie, K., Shibata, K., Inoue, N., Iizuka, T., Takebe, G., Takahashi, K., Nishihira, J., Izumi, H., Sakamoto, W. (2004). Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology 197:93-100.
15. Jensen, C. E., Tuck, S. M., Agnew, J. E., et al. (1998). High incidence of osteoporosis in thalassemia major. J. Pediat. Endocrinol Metabol. 11 Suppl 3:975-977.
16. Kartsogiannis, V., Zhou, H., Horwood, N. J., et al. (1999). Localization of RANKL (receptor activator of NF-κB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25:525-534.
17. Lacey, D. L., Tan, H. L., Lu, J., et al., (1999). Osteoprotegerin ligand is essential for osteoclast survival in vitro and in vivo. J. Bone Mine. Res. 14 (1):1182-1195.
18. Lacey, D. L., Timms, E., Tan, H. L., et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
19. Lurn, L., Wong, B. R., Josien, R., et al, (1999). Evidence for a role of a tumor necrosis factor-α (TNF-α) converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274:13613-13618.
20. Massey, H. M., Scopes, J., Horton, M. A., Flanagan, A. M. (2001). TGF-β stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment. Bone 28:577-582.
21. Mahdy, K. A., Ahmed, H. H., Mannaa, F., Azza Abdel-Shaheed, A. (2007). Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases. World J. Gastroenterol. 13 (5):785-790.
22. Morabito, N., Gaudio, A., Lasco, A., Atteritano, M., Pizzoleo, M. A., Cincotta, M., La Rosa, M., Guarino, R., Anna Meo, A., Frisina, N. (2004). Osteoprotegerin and RANKL in the pathogenesis of thalassemia induced osteoporosis: new pieces of the puzzle. J. Bone Miner. Res. 19:722-727.
23. Nagai, M.; Sato, N. (1999). Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun. 257:719-723.
24. Richardson, J. C., Hassell, A. B., Thomas, E., Hay, E. M. (2004). GPs' perceptions of the role of DEXA scanning: an exploratory study. Fam. Pract. 21 (1):51-53.
25. Vega, D., Maalouf, N. M., Khashayar, Sakhaee, K. (2007). The role of receptor activator of nuclear factor κB (RANK)/RANK Ligand/ Osteoprotegerin: clinical implications. J. Clin. Endocrinol. Metab. 92 (12):4514-4521.
26. Voskaridou, E., Stoupa, E., Antoniadou, L., Premetis, E., Konstantopoulos, K., Papassotiriou, L., Terpos, E. (2006). Osteoporosis and osteosclerosis in sickle cell/b-thalassemia: the role of the RANKL/Osteoprotegerin axis. Haematologica 91 (6):813-816.
27. Voskaridou, E., Terpos, E., Spina, G., et al., (2003). Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br. J. Haematol. 123:730-737.
28. World Health Organization (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization Technical Report Series 843:1-129.
29. Yasuda, H., Shima, N., Nakagawa, N., et al. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337.
30. Voskaridou, E., Anagnostopoulos, A., Konstantopoulos, K., Stoupa, E., Spyropoulou, E., Kiamouris, C., Terpos, E. (2006). Zoledronic acid for the treatment of osteoporosis in patients with b-thalassemia: results from a single-center, randomized, placebocontrolled trial. Haematologica 91 (9):1193-1202.
31. Yano, K., Tsuda, E., Washida, N., et al. (1999). Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14:518-527.